Skip to main content

Healthy Male and Female Subjects

6
Pipeline Programs
7
Companies
7
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
6
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
2100%
+ 6 programs with unclassified modality

Competitive Landscape

7 companies ranked by most advanced pipeline stage

NeuroDawn Pharmaceutical
2 programs
2
Y-4 tabletPhase 11 trial
Y-4 tabletPhase 11 trial
Active Trials
NCT06935721Recruiting10Est. Jun 2025
NCT07013773Recruiting20Est. Jul 2025
Alvotech
AlvotechLUXEMBOURG, Luxembourg
1 program
1
AVT80Phase 11 trial
Active Trials
NCT06732804Completed385Est. Jan 2026
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
DapagliflozinPhase 1Small Molecule
Berlin-Chemie
Berlin-ChemieGermany - Berlin
1 program
1
Ibuprofen 2%Phase 1
Menarini
MenariniGermany - Dresden
1 program
1
Ibuprofen 2%Phase 11 trial
Active Trials
NCT07036861Completed74Est. Jan 2025
Spiderwort
SpiderwortON - Ottawa
1 program
CelluJuve®N/A2 trials
Active Trials
NCT07545980Not Yet Recruiting12Est. Jul 2028
NCT06930209Active Not Recruiting10Est. Apr 2027
Bristol Myers Squibb
1 program
DapagliflozinPHASE_1Small Molecule1 trial
Active Trials
NCT00546741Completed18Est. Feb 2008

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
NeuroDawn PharmaceuticalY-4 tablet
NeuroDawn PharmaceuticalY-4 tablet
AlvotechAVT80
MenariniIbuprofen 2%
Bristol Myers SquibbDapagliflozin
SpiderwortCelluJuve®
SpiderwortCelluJuve®

Clinical Trials (7)

Total enrollment: 529 patients across 7 trials

NCT07013773NeuroDawn PharmaceuticalY-4 tablet

To Evaluate the Effect of Food on the Pharmacokinetics of Y-4 Tablets in Healthy Subjects

Start: May 2025Est. completion: Jul 202520 patients
Phase 1Recruiting
NCT06935721NeuroDawn PharmaceuticalY-4 tablet

Pharmacokinetics of Y-4 Tablets With Pregabalin Capsules and Riluzole Tablets in Chinese Healthy Subject

Start: Mar 2025Est. completion: Jun 202510 patients
Phase 1Recruiting
NCT06732804AlvotechAVT80

Study to Investigate Comparative Pharmacokinetics, Safety, Immunogenicity and Tolerability Between AVT80 and Entyvio

Start: Feb 2025Est. completion: Jan 2026385 patients
Phase 1Completed
NCT07036861MenariniIbuprofen 2%

A Comparative Bioavailability Study of Reformulated Ibuprofen 2% and 4% Oral Suspensions (Berlin Chemie AG) and Versus Ibuprofen (Nurofen®) 200 mg/5 ml Oral Suspension

Start: Nov 2023Est. completion: Jan 202574 patients
Phase 1Completed
NCT00546741Bristol Myers SquibbDapagliflozin

Drug Interaction With Metformin

Start: Nov 2007Est. completion: Feb 200818 patients
Phase 1Completed
NCT07545980SpiderwortCelluJuve®

CelluJuve® for the Treatment of Moderate to Severe NLFs

Start: Apr 2026Est. completion: Jul 202812 patients
N/ANot Yet Recruiting
NCT06930209SpiderwortCelluJuve®

Histological Analysis of CelluJuve® Injections in the Brachium

Start: Mar 2025Est. completion: Apr 202710 patients
N/AActive Not Recruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 actively recruiting trials targeting 529 patients
7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.